Prevalence and cumulative 5-year incidence of chronic lymphocytic leukemia in the adult population in the Russian Federation and Ukraine: Data from the LEUKOSPECT study

Vasylyev, Averyan; Loginov, Alexander; Molostvova, Valentina; Ребров, Б. А.; Pereira, Marcelo Horacio S.; Melo, Caroline Wirtzbiki A.; Makarova, Janina; Pashanov, Evgeny D.; Mysnik, Andriy

doi:10.1080/10245332.2016.1201630

Cited by 3 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite previously described epidemiological differences in Chronic Lymphocytic Leukemia (CLL) incidence and prognosis, [1][2][3][4] CLL has not been assessed in larges series in multicultural developing countries.…”

Section: Chronic Lymphocytic Leukemia In Brazil: a Retrospective Analmentioning

confidence: 99%

Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases

et al. 2017

View full text Add to dashboard Cite

Section: Chronic Lymphocytic Leukemia In Brazil: a Retrospective Analmentioning

confidence: 99%

Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases

et al. 2017

View full text Add to dashboard Cite

“…117047) was the first epidemiologic study of CLL in these post-Soviet countries. The first part of the study was aimed at assessing the prevalence (in 2013) and cumulative 5-year (2009–2013) incidence of CLL; these data were published in a separate manuscript 6 and will not be discussed further here. This paper focusses on the investigation of SoC, health care resource utilization, and DMCs in 2013 in the adult populations of cities across three post-Soviet countries – the Russian Federation (Russia), Ukraine, and Kazakhstan.…”

Section: Introductionmentioning

confidence: 99%

Standard of care and direct medical costs of the treatment of chronic lymphocytic leukemia among the adult population in Ukraine, Russia, and Kazakhstan: data from the LEUKOSPECT study

Vasylyev¹,

Molostvova²,

Ребров

et al. 2017

CMAR

Self Cite

View full text Add to dashboard Cite

PurposeThe LEUKOSPECT study aimed to describe health service utilization and to estimate the direct medical costs (DMCs) of chronic lymphocytic leukemia (CLL) in 2013 in the adult population of three post-Soviet countries – Russia, Ukraine, and Kazakhstan. As oncologic medical care is provided by federal state-owned, specialized medical institutions, the cost estimation in this study primarily informs from a state budget perspective. Patients’ contributions to medical costs were not included in the cost evaluation.Patients and methodsThis was a multinational, multicenter, retrospective study conducted in eight specialized centers (four in Russia, three in Ukraine, and one in Kazakhstan). The investigators captured data from the medical documents of all adult patients with an established CLL diagnosis before December 31, 2013, and who made at least one visit to their respective center between January 1 and December 31, 2013.ResultsA total of 319 adult CLL patients were enrolled (124 in Kazakhstan, 106 in Russia, and 89 in Ukraine). In 2013, the DMCs of CLL management (without CLL therapy) were €215.40 in Kazakhstan, €1,342.20 in Russia, and €13,260.70 in Ukraine. Hospitalizations formed the largest proportion of total cost: 18.1%, 23.1%, and 40.4%, respectively. The mean cost of CLL medical treatment was €13,580.60 (Russia), €399.40 (Kazakhstan), and €7,453.00 (Ukraine).ConclusionCLL treatment standards varied across the selected countries; higher usage of biologic therapy was noted in Russia. Future research is needed to assess DMCs which include CLL treatment, which is another essential factor contributing to CLL DMCs.

show abstract

“…In the present study, CLL was the most common type of mature B cell neoplasm (68%) and this was consistent with that documented in Baghdad 13 and Turkey 14 that confirmed CLL frequencies of 65.9%, 72.8% respectively The median age at diagnosis in the current study was 57.5 years with a peak incidence between 41 to 60 years which was close to that recorded previously in Erbil (65 years), 15 Baghdad (61 years) 13 and turkey (64.4 years). 14 In Western countries, on the other hand, the median age at diagnosis is more with a range (67 -72 years), 16 Male dominance has been found in the current study (66.2%) with male to female ratio of (1.95/1) which was accordance with the results of Hasan et al, 15 Hellek et al 17 and Padaro et al 18 In the present study the clinical symptoms of easy fatigability (50%), lymphadenopathy (41.2%), splenomegaly (41.2%), joint pain (30.9%), abdominal pain (29.4%), fever (26.5%) were the most presenting symptoms of CLL, and these symptoms were documented less frequently in the present study compared with previous study done in Erbil, 15 which recorded splenomegaly as most frequent clinical features (64.8%), lymphadenopathy(60%) and hepatomegaly (21.9%), a study done in Baghdad found that the most presenting features were lymphadenopathy (50%) followed by splenomegaly (35%), pallor (30%), hepatomegaly (22%) and fever (20%), 13 however, Previous studies have been well recorded the diversity of clinical presentations in CLL and their associations with ethnic background. 19,20 According to the literature, 30-35% of CLL cases were diagnosed accidentally, 21 however the current study reported (17.6%) of patients were diagnosed accidentally, probably due to late-stage disease presentation, deficiencies in the referring system, and a loss of regular health checkup behavior in our population.…”

mentioning

confidence: 99%

Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

Mazin Butrous,

Sadiq Muhammad

2023

Zanco J Med Sci

View full text Add to dashboard Cite

Background and objective: Chronic lymphocytic leukemia (CLL) is a clonal, mature B-cell neoplasm, its clinical features, cell morphology, and immunophenotyping are used to establish the diagnosis. Immunophenotyping by flow cytometry is the most accurate procedure for diagnosing CLL, there is no single marker exclusively expressed in CLL, however, a complex of immunophenotypic markers that incorporates several B-cell markers and assists in differentiating CLL from other mature B-cell neoplasms, the expression of these immunophenotypic markers is considered in the specific CLL scoring system (Moreue scoring system).this study aimed to assess the clinico – hematological features and immunophenotypic characteristics of CLL patients and to assess the role of immunophenotyping in the differential diagnosis of CLL. Methods: an observational prospective and retrospective study was carried out at Nanakaly hospital for blood diseases and oncology in Erbil city, Iraq. That was conducted on 100 patients newly diagnosed with mature B cell neoplasm which included 68 cases of CLL and 32 cases with other mature B cell neoplasm (MBN), usinga convenience sampling method. The study period was from the1st of September 2021 to the end of April 2022. An interview questionnaire was used to collect the study data from the patients. Results: The mean of age ± standard deviation of the CLL patients (58.85 ± 10.69) years and (66.2%) was male, The most frequent clinical presentations for CLL cases were fatigue (50%), lymphadenopathy (41.2%), and splenomegaly (41.2%), (50%) of CLL patients had anemia, thrombocytopenia was seen in (32.4%) and leukocytosis was seen (98.5%), all patients had lymphocytosis and (97%) had an absolute B lymphocyte count of more than 5 x109 /L. all the studied CLL patients expressed both CD45 and CD19 markers, the expression of the immunophenotypic markers was as following: CD5 (98.5%), CD23 (97.1%) and CD200 (97.1%), Half of the patients (50%) showed expression of monoclonal lambda light chain, sIgM (4.4%), CD20 (88.2%) and CD43 (54.4%) and CD38 (26.5%). The expression of the following marker had a significant role in the differentiation between CLL and other MBN: CD5, CD23, CD79b, FMC7, sIgM, CD200, and CD43. Conclusion: Our results have shown that the clinical presentations and hematological profile of Iraqi CLL patients were not significantly different from that of previous local and global studies, the distinct immunophenotyping, as well as it has been found that immunophenotyping is a promising method for supporting the clinical and morphological characterization of CLL.

show abstract

Prevalence and cumulative 5-year incidence of chronic lymphocytic leukemia in the adult population in the Russian Federation and Ukraine: Data from the LEUKOSPECT study

Cited by 3 publications

References 11 publications

Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases

Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases

Standard of care and direct medical costs of the treatment of chronic lymphocytic leukemia among the adult population in Ukraine, Russia, and Kazakhstan: data from the LEUKOSPECT study

Study of immunophenotypic markers and clinico-hematological findings in chronic lymphocytic leukemia

Contact Info

Product

Resources

About